Literature DB >> 19807634

A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia.

Revle D Bangor-Jones1, Gary K Dowse, Carolien M Giele, Paul G van Buynder, Meredith M Hodge, Mary M Whitty.   

Abstract

OBJECTIVE: To describe a prolonged outbreak of mumps in the Kimberley region of Western Australia in 2007-2008.
DESIGN: Descriptive analysis of all mumps cases notified to the WA Notifiable Infectious Diseases Database for the period 1 July 2007 to 30 June 2008. MAIN OUTCOME MEASURES: Notified cases of mumps by patients' place of residence, age, Indigenous or non-Indigenous ethnicity, vaccination status and method of diagnosis.
RESULTS: 84% (153/183) of mumps notifications in WA over the study period occurred in the Kimberley region or were directly linked to Kimberley cases. Median age of patients was 18 years (range, 2-63 years), and 54% of patients were aged less than 20 years. Almost all (92%) were Australian Aboriginal people; 67% (102/153) had received at least one dose of mumps vaccine, and 52% had received two doses. The highest notification rate (1816 cases per 100,000 population) was in the Aboriginal 15-19-years age group, and 92% of these patients had received at least one dose of mumps vaccine. Almost all outbreak cases (94%) were laboratory confirmed. Genotyping was performed on 20 mumps virus isolates: all were genotype J.
CONCLUSION: A prolonged outbreak of mumps occurred in a well defined, highly vaccinated, predominantly young Aboriginal population in the remote Kimberley region of WA. This outbreak raises questions about the effectiveness and scheduling of the current vaccine (which is genotype A-derived), especially for Aboriginal people. Surveillance of circulating mumps virus genotypes and neutralisation studies will help in evaluating the protection provided by the current vaccine against genotypically different strains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19807634     DOI: 10.5694/j.1326-5377.2009.tb02850.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  14 in total

1.  Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.

Authors:  Steven A Rubin; Malen A Link; Christian J Sauder; Cheryl Zhang; Laurie Ngo; Bert K Rima; W Paul Duprex
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Environmental factors potentially associated with mumps transmission in yeshivas during a mumps outbreak among highly vaccinated students: Brooklyn, New York, 2009-2010.

Authors:  Amy Parker Fiebelkorn; Jennifer B Rosen; Cedric Brown; Christopher M Zimmerman; Hyman Renshowitz; Christopher D'Andrea; Kathleen M Gallagher; Rafael Harpaz; Jane R Zucker
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

3.  Epidemiology and the economic assessment of a mumps outbreak in a highly vaccinated population, Orange County, New York, 2009-2010.

Authors:  Preeta Krishnan Kutty; Jacqueline Lawler; Elizabeth Rausch-Phung; Ismael R Ortega-Sanchez; Stephen Goodell; Cynthia Schulte; Lynn Pollock; Barbara Valure; Jean Hudson; Kathleen Gallagher; Debra Blog
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

4.  Monitoring Viral Genetic Variation as a Tool To Improve Molecular Diagnostics for Mumps Virus.

Authors:  Meik Dilcher; Kevin Barratt; Jennifer Douglas; Andrew Strathdee; Trevor Anderson; Anja Werno
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

5.  Epidemiologic features of mumps in Taiwan from 2006 to 2011: a new challenge for public health policy.

Authors:  Chian-Ching Chen; Chien-Chih Lu; Bo-Hua Su; Kow-Tong Chen
Journal:  World J Pediatr       Date:  2014-11-22       Impact factor: 2.764

Review 6.  Molecular biology, pathogenesis and pathology of mumps virus.

Authors:  Steven Rubin; Michael Eckhaus; Linda J Rennick; Connor G G Bamford; W Paul Duprex
Journal:  J Pathol       Date:  2015-01       Impact factor: 7.996

7.  Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine.

Authors:  Donald R Latner; Amy Parker Fiebelkorn; Marcia McGrew; Nobia J Williams; Laura A Coleman; Huong Q McLean; Steven Rubin; Carole J Hickman
Journal:  Open Forum Infect Dis       Date:  2017-12-08       Impact factor: 3.835

8.  Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine.

Authors:  Amy Parker Fiebelkorn; Laura A Coleman; Edward A Belongia; Sandra K Freeman; Daphne York; Daoling Bi; Cheryl Zhang; Laurie Ngo; Steven Rubin
Journal:  Open Forum Infect Dis       Date:  2014-10-18       Impact factor: 3.835

9.  Mumps postexposure prophylaxis with a third dose of measles-mumps-rubella vaccine, Orange County, New York, USA.

Authors:  Amy Parker Fiebelkorn; Jacqueline Lawler; Aaron T Curns; Christina Brandeburg; Gregory S Wallace
Journal:  Emerg Infect Dis       Date:  2013       Impact factor: 6.883

10.  In vitro inhibition of mumps virus by retinoids.

Authors:  Kaitlin J Soye; Claire Trottier; Thomas Z Di Lenardo; Katherine H Restori; Lee Reichman; Wilson H Miller; Brian J Ward
Journal:  Virol J       Date:  2013-11-14       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.